News - Pfizer, Xeljanz

Filter

Current filters:

PfizerXeljanz

Popular Filters

Systemic psoriasis market forecast to reach $10.4 billion by 2020

05-02-2014

The systemic psoriasis treatment market value in the eight major countries (8MM) - the USA, Canada, France,…

AmgenapremilastBiotechnologybrodalumabCelgeneDermatologicalsEli LillyMarkets & MarketingNovartisPfizersecukinumabXeljanz

Pfizer sees mixed top-line results in the first two of five phase III clinical trials of tofacitinib

Pfizer sees mixed top-line results in the first two of five phase III clinical trials of tofacitinib

09-10-2013

Pfizer has announced mixed top-line results from two Phase III clinical trials of tofacitinib for the…

DermatologicalsNorth AmericaPfizerPharmaceuticalResearchtofacitinibXeljanz

Disappointment for Pfizer on negative CHMP view for Xeljanz

26-07-2013

There was disappointment for US pharma behemoth Pfizer (NNYSE: PFE), when the European Medicines Agency's…

Anti-Arthritics/RheumaticsEuropePfizerPharmaceuticalRegulationXeljanz

Pfizer gets Swiss nod for Xeljanz for rheumatoid arthritis

16-07-2013

US drug giant Pfizer (NYSE: PFE) said its rheumatoid arthritis (RA) therapy Xeljanz (tofacitinib) has…

Anti-Arthritics/RheumaticsEuropePfizerPharmaceuticalRegulationTakeda NycomedXeljanz

New EULAR recommendations address use of synthetic and biological DMARDs

05-07-2013

The European League Against Rheumatism (EULAR) has this week released updated recommendations for the…

ActemraBiotechnologyBristol-Myers SquibbEuropeHealthcareMabTheraOrenciaPfizerPharmaceuticalRegulationRocheXeljanz

Rise of rheumatoid arthritis therapies: JAK inhibitor battle and biosimilar threats

26-06-2013

An approval of US drug major Eli Lilly (NYSE: LLY) and Incyte Pharmaceuticals'(Nasdaq: INCY) drug baricitinib…

Anti-Arthritics/RheumaticsbaricitinibBiotechnologyEli LillyIncyteMarkets & MarketingPfizerPharmaceuticalPricingXeljanz

EMA committee gives thumbs down for Pfizer's Xeljanz for RA

26-04-2013

Shares of Pfizer (NYSE: PFE) fell 2.4% to $29.53 in extended New York trading yesterday, after the pharma…

Anti-Arthritics/RheumaticsEuropePfizerPharmaceuticalRegulationXeljanz

US Senator calls for re-examination of pricing of drugs developed with public funds

20-03-2013

US Senator Ron Wyden (Democrat, Oregon) has released a letter written to National Institutes of Health…

North AmericaPfizerPharmaceuticalPoliticsPricingResearchXeljanz

Newly approved tofacitinib slows rheumatoid arthritis joint damage

24-01-2013

A Phase III clinical trial demonstrates that tofacitinib improves disease activity and inhibits progression…

Anti-Arthritics/RheumaticsPfizerPharmaceuticalResearchtofacitinibXeljanz

FDA approves Pfizer's Xeljanz for rheumatoid arthritis

07-11-2012

Having in the summer put back its "action date" due to a request for additional analysis of the existing…

Anti-Arthritics/RheumaticsNorth AmericaPfizerPharmaceuticalRegulationtofacitinibXeljanz

Back to top